Physician profile
Meagen M Mccusker
NPI 1861651432
$1,818,459.58
in general payments reported to CMS, 2019-2025
51 companies · $520K in 2025
The $520K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129K · 2020: $61K · 2021: $103K · 2022: $266K · 2023: $326K · 2024: $413K · 2025: $520K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $866K · Consulting Fee: $193K · Travel and Lodging: $145K · Food and Beverage: $45K · Honoraria: $10K · Education: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $866,268.50 |
| Consulting Fee | $192,901.42 |
| Travel and Lodging | $144,566.26 |
| Food and Beverage | $44,672.56 |
| Honoraria | $10,200.00 |
| Education | $288.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $570,364.92 | 2019-2025 | |
| Genzyme Corporation | $282,979.53 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $259,144.06 | 2019-2025 | Dupixent, Libtayo |
| Amgen INC. | $182,256.17 | 2021-2025 | Otezla, Otezla |
| Pfizer INC. | $116,111.78 | 2019-2025 | |
| Lilly USA, LLC | $103,777.00 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Ucb, INC. | $87,118.79 | 2019-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $53,573.37 | 2021-2025 | Opzelura, Opzelura |
| Arcutis Biotherapeutics, INC. | $42,305.85 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $27,721.16 | 2019-2025 | Tremfya, Remicade, Stelara |
| Leo Pharma INC. | $26,004.44 | 2019-2025 | Adbry, Anzupgo, Spevigo |
| Dermavant Sciences, INC. | $19,423.74 | 2023-2024 | Vtama |
| Organon LLC | $16,952.74 | 2024-2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $7,691.43 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $4,831.95 | 2020-2025 | Winlevi, Absorica Ld, Ilumya |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meagen Mccusker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.